AMPE - Ampio Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Ampio Pharmaceuticals, Inc.

373 Inverness Parkway
Suite 200
Englewood, CO 80112
United States
720-437-6500
http://www.ampiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedAge
Mr. Michael MacalusoFounder, Chairman & CEO305kN/A65
Dr. David Bar-Or M.D.Chief Scientific Officer & Director305kN/A68
Mr. Philip H. CoelhoDirector89kN/A73
Mr. Thomas E. Chilcott IIICFO & Sec.N/AN/A49
Ms. Holli CherevkaChief Operating OfficerN/AN/A34
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Corporate Governance

Ampio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.